1. Askenase PW, Hayden BJ, Gershon RK (1975) Augmentation of delayed type hypersensitivity by doses of cyclophospamide which do not affect antibody responses. J Exp Med 141: 697–702
2. Berd D, Mastrangelo MJ (1987) Elimination of immune suppressor mechanisms in humans by oxazaphosphorines. Methods Find Exp Clin Pharmacol 9: 569–577
3. Berd D, Maguire HC, Mastrangelo MJ (1984) Impairment of concanavalin A-inducible suppressor activity following administration of cyclophosphamide to patients with advanced cancer. Cancer Res 44: 1275–1280
4. Blomgren H (1985) Role of monocytes in the modulation of mitogenic responses of human blood lymphocytes by Ru 41, 740, a glucoprotein extract ofKlebsiella pneumoniae. Immunol Immunopharmacol (EOS) 5: 169–175
5. Blomgren H (1989) Influence of low doses of an oxazaphosphorine on natural killer activity of human lymphocytes. Cancer Immunol Immunother 29: 151–153